Theriva Biologics (TOVX) Gains from Investment Securities (2014 - 2026)
Theriva Biologics (TOVX) posted quarterly Gains from Investment Securities of $27000.0 for Q1 2026, up 28.57% year-over-year from $21000.0 in Q1 2025, and up 103.48% quarter-over-quarter from -$775000.0 in Q4 2025.
Theriva Biologics (TOVX) Gains from Investment Securities (2014 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Gains from Investment Securities for 10 consecutive years, with $27000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 28.57% year-over-year to $27000.0; the TTM figure through Mar 2026 stood at $9.0 million (up 1644.59% YoY), while the FY2025 annual figure was $9.0 million, up 1191.99% from the prior year.
- Gains from Investment Securities climbed to $27000.0 in Q1 2026 per TOVX's latest filing, from -$775000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $9.2 million in Q2 2025 and bottomed at -$1.6 million in Q3 2023.
- Historically, Gains from Investment Securities has averaged $803875.0 across 5 years, with a median of $214500.0 in 2022.
- Annual changes were most pronounced in 2023 — Gains from Investment Securities slumped 790.31% — and 2025, when it jumped 3428.0%.
- Theriva Biologics' Gains from Investment Securities stood at $2.3 million in 2022, then tumbled by 52.46% to $1.1 million in 2023, then plunged by 83.33% to $185000.0 in 2024, then plunged by 518.92% to -$775000.0 in 2025, then surged by 103.48% to $27000.0 in 2026.
- Business Quant data shows TOVX's Gains from Investment Securities at $27000.0 in Q1 2026, -$775000.0 in Q4 2025, and $633000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -212,000.00 |
| Jun 30, 2026 | -212,000.00 |
| Mar 31, 2026 | 27,000.00 |
| Mar 31, 2026 | 27,000.00 |
| Dec 31, 2025 | -775,000.00 |
| Dec 31, 2025 | -775,000.00 |
| Sep 30, 2025 | 633,000.00 |
| Sep 30, 2025 | 633,000.00 |
| Jun 30, 2025 | 9.15 Mn |
| Jun 30, 2025 | 9.15 Mn |
| Mar 31, 2025 | 21,000.00 |
| Mar 31, 2025 | 21,000.00 |
| Dec 31, 2024 | 185,000.00 |
| Dec 31, 2024 | 185,000.00 |
| Sep 30, 2024 | 587,000.00 |
| Sep 30, 2024 | 587,000.00 |
| Jun 30, 2024 | -275,000.00 |
| Jun 30, 2024 | -275,000.00 |
| Mar 31, 2024 | 202,000.00 |
| Mar 31, 2024 | 202,000.00 |